Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1801342-60-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Programmed cell death protein 1 (PD-1) immune-checkpoint inhibitormonoclonal antibody
Mechanism of action
Binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1-mediated inhibition of antitumour T-cell activity and restoring immune recognition and killing of tumour cells.
Indications / reported uses
Treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients who are not candidates for curative surgery or radiation
Treatment of locally advanced or metastatic basal cell carcinoma (BCC) after hedgehog pathway inhibitor therapy or when such therapy is inappropriate
Treatment of selected advanced non-small-cell lung cancer (NSCLC) settings; combination and biomarker criteria depend on current product label and jurisdiction
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Cemiplimab Environmental Risk Assessment (ERA) (the Cemiplimab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.